Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026

Relay Therapeutics, Inc.

2023-FY EPS reported -$2.79 revenue$25,546,000

Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.
Full year 2023 net loss $342.0M ($2.79 per share) vs $290.5M in 2022.
Cash, cash equivalents and investments $750.1M at Dec 31, 2023; expected to fund operations into H2 2026.
Completed enrollment in RLY-2608 600mg + fulvestrant dose expansion; initiated additional cohorts and triplet with ribociclib.
Deprioritized further clinical development of RLY-5836.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Relay Therapeutics, Inc. reported the full year 2023 results: revenue Revenue was $25.5 million for the full year 2023, net income Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79, EPS $2.79.

Period: the full year 2023
Revenue: Revenue was $25.5 million for the full year 2023
Net income: Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79
EPS: $2.79
Result: reported results

Exact text from the filing

Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Relay Therapeutics, Inc. reported the fourth quarter of 2023 results: net income Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67, EPS $0.67.

Period: the fourth quarter of 2023
Net income: Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67
EPS: $0.67
Result: reported results

Exact text from the filing

Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.